AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application.

Listing of Claims:

- 1-12, (cancelled).
- 13. (previously presented) A compound according to Formula III,

or a pharmaceutically acceptable salt thereof, wherein:

- R^{1a} is selected from halogen, lower perfluoroalkyl, -NO₂ and optionally substituted C_{1-4} alkyl; and R^{1b} is selected from halogen, -N(R^5) R^5 , -S R^5 , perfluoroalkyl, and optionally substituted lower alkyl;
- R³ is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -OR5, -N(R5)OR5, -ON(R5)R5, -N(R5)N(R5)R5, -N(R5)R5, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;

R5a is H:

each R⁵ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

- two of R⁵, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;
- each R⁶ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂, -OR⁵,
 -N(R⁵)R⁵, -S(O)₀₋₂R⁵, -SO₂N(R⁵)R⁵, -CO₂R⁵, -CO₂R⁵, -C(O)N(R⁵)R⁵, -N(R⁵)SO₂R⁵,
 -N(R⁵)C(O)R⁵, -N(R⁵)CO₂R⁵, -C(O)R⁵, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclylakyl, and optionally substituted arylalkyl; or
- two of R⁶, together with the atom or atoms to which they are attached, can combine to form one of an optionally substituted three to seven-membered alicylic, and an optionally substituted three to seven-membered heteroalicylic;
- each R⁷ is independently selected from -H, -CN, -NO₂, -N(R⁵)R⁵, -OR⁵, -S(O)₀₋₂R⁵, -SO₂N(R⁵)R⁵, -CO₂R⁵, optionally substituted lower alkenyl, and optionally substituted lower alkenyl, and optionally substituted lower alkenyl; or
- R⁵ and R⁷, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;
- each of X and Y is independently selected from -C(=O)-, -C(R⁶)R⁶-, -O-, -N(R⁵)-, -C(=NR⁷)-, and -S(O)₀₋₂-; provided when X is -O- or -N(R⁵)-, then Y cannot contain phenyl, napthyl, cyclohexyl, dihydronapthyl tetrahydronapthyl, or a five- to six-membered heteroaryl, each optionally substituted; and

O is either =N- or =C(H)-.

- (previously presented) The compound according to claim 13, wherein R^{la} is selected from -NO₂, halogen, perfluoroalkyl, haloalkyl, and optionally substituted C_{1,2}alkyl.
- 15. (original) The compound according to claim 14, wherein R^3 is selected from optionally substituted -O-C₁₋₄alkyl, -O-C₁₋₄perfluoroalkyl, optionally substituted -N(H)C₁₋₄alkyl, optionally substituted -N(C₁₋₄alkyl, and optionally substituted -S(O)₀₋₂-C₁₋₄alkyl, and optionally substituted -S(O)₀₋₂-C₁₋₄perfluoroalkyl.
- 16. (original) The compound according to claim 15, wherein Y is either -N(H)- or -C(R⁶)R⁶-.

- (original) The compound according to claim 16, wherein X is selected from -O-, -N(R⁵)and -S-.
- 18. (original) The compound according to claim 17, wherein Y is $-C(R^6)R^6$ -; wherein each R^6 is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted $-O-C_1$.

 4. 4alkyl, optionally substituted $-N(H)C_{1-4}$ alkyl, optionally substituted $-S-C_{1-4}$ alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.
- 19. (original) The compound according to claim 18, wherein Y is $-C(H)R^6$ -; wherein R^6 is independently selected from -H, halogen, trihalomethyl, -NH₂, optionally substituted -O-C₁- $_4$ alkyl, optionally substituted -N(H)C₁₋₄alkyl, optionally substituted -S-C₁₋₄alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.
- (original) The compound according to claim 19, wherein Q is =C(H)-.
- 21-28. (cancelled)
- (previously presented) The compound according to claim 13, wherein R^{1a} is selected from halo, lower perfluoroalkyl, -NO₂, and optionally substituted C_{1.4}alkyl.
- 30-33. (cancelled)
- 34. (currently amended) A compound selected from Table 3.

Table 3

	Table	
Entry	Name	Structure
1	2-[(3-cyano-4,6-dimethyl-5- nitropyridin-2-yl)oxy]-N-[3- (trifluoromethyl)phenyl]acetamide	O ₂ N CN CF ₃
5	N ² -[2-amino-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S H ₂ N H O CF ₃

5

Tel. 312-913-0001

Table 3

Entry	Name	Structure
7	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(methyloxy)phenyl]acetamide	S N H
9	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (4-chlorophenyl)acetamide	H ₂ N N S H
11	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (3-chlorophenyl)acetamide	H ₂ N S O
14	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	S N H F F
16	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- methyl-N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N S CF ₃
17	N ² -[4-amino-6 (methylthio) 1,3,5- triazin 2 yl] N [3- (trifluoromethyl)phenyl]glycinamide	H ₂ N N H CF ₃

Entry	Name	Structure
20	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H CF3
30	2-amino-4-({2-[2,5- bis(methylkox)phenyl]-2- oxoethyl}thio)-6- (methylthio)pyrimidine-5-carbonitrile	H ₂ N S
31	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-fluoro-3- (trifluoromethyl)phenyl]acetamide	H ₂ N CN CF ₃
34	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-chloro-3- (trifluoromethyl)phenyl]acetamide	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
35	2-amino-4-(methylthio)-6-({2-oxo-1- [3-(trifluoromethyl)phenyl]pyrrolidin- 3-yl}thio)pyrimidine-5-carbonitrile	H ₂ N CN CF ₃
36	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [6-(trifluoromethyl)pyridin-2- yl]acetamide	H ₂ N CN N CF ₃

Entry	Name	Structure
37	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-(trifluoromethyl)pyridin-2- yl]acetamide	$\begin{array}{c c} S & CN \\ N & S & N \\ N & S & N \end{array}$
41	2-{[2-(acetylamino)-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(trifluoromethyl)phenyl]acetamide	
42	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	$-s \longrightarrow H_{2N} \longrightarrow F F$
45	2-{[2-amino-5-formyl-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	E E E E E E E E E E E E E E E E E E E
46	2-{[2-amino-5-formyl-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	N N N N N N N N N N N N N N N N N N N
47	2-[[4-amino-6 (methylthio) 1,3,5- triazin-2-yl]oxy] N [3- (trifluoromethyl)phenyl]acetamide	S O H F

Table 3

Entry	Name	Structure
54	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-(methyloxy)-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N S O CF ₃
55	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-chloro-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N S N C C
58	N²-[2-amino-5-[(E)- hydrazonomethyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	NH ₂
59	N²-[2-amino-5-[(E)- (hydroxyimino)methyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	NH ₂
60	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂ N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
61	2-{[2-amino-5-cyano-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	NH NN S H F F
62	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-amino-5- (trifluoromethyl)phenyl]acetamide	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
63	2-amino-4-(methylthio)-6-({[6- (trifluoromethyl)-1H-benzimidazol-2- yl]methyl}thio)pyrimidine-5- carbonitrile	H ₂ N S N F F
64	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S I I I I I I I I I I I I I I I I I I I
65	N ² -[5-cyano-2-(methylamino)-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	
66	2-{[2-amino-5-cyano-6- (dimethylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	N N N S N N S N F

Table 3

Entry	Name	Structure
67	(S)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	N O F F F F
68	(2R)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	$-s \longrightarrow N \longrightarrow F F$ $N \longrightarrow N \longrightarrow N \longrightarrow N$ $H_2N \longrightarrow N \longrightarrow N$
69	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S N O N F F F
70	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-3- methyl-N-[3- (trifluoromethyl)phenyl]butanamide	H ₂ N O HN F
72	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]glycinamide	S N H ₂ N N O F F
73	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}- N-[3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S H O N F F

Table 3

Entry	Name	Structure
74	N ² -[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	Sa O N H ₂ N H O F F
75	N ² -[2-amino-5-cyano-6- (methylsulfonyl)pyrimidin-4-yl]-N- [3-(trifluoromethyl)phenyl]-L- alaninamide	ODE N H ₂ N H O F F
76	N ² -(5-cyano-2-morpholin-4- ylpyrimidin-4-yl)-N-[3- (trifluoromethyl)phenyl]glycinamide	N H F F
78	N²-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	$\begin{array}{c c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$
79	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- (methyloxy)-5- (trifluoromethyl)phenyl]-L- alaninamide	S N H ₂ N CF ₃
80	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- chloro-5-(trifluoromethyl)phenyl]-L- alaninamide	S N H CF3

Table 3

Entry	Name	Structure
83	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D- alaninamide	S I I I CF3
84	2-[(2-amino-5-cyano-6-morpholin-4-ylpyrimidin-4-yl)thio]-N-[3- (trifluoromethyl)phenyl]acetamide	F Z Z S S S S S S S S S S S S S S S S S
85	(R)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	N O N F F F
86	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S CN NH2 NH2 CF3
87	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-[2- (dimethylamino)ethyl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H CF3
88	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H CF ₃

Table 3

Entry	Name	Structure
89	N ² -(2,6-diamino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	H ₂ N H O CF ₃
90	N ² -(2-amino-5-cyanopyrimidin-4-yl)- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N H O CF ₃
91	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	S CN H ₂ N N CF ₃
93	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-1,2- dimethyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S CN CF3
94	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- amino-5-(trifluoromethyl)phenyl]-L- alaninamide	S CN H ₂ N H O NH ₂
95	ethyl [1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2-({[3- (trifluoromethyl)phenyl]amino}carbo nyl)hydrazino]acetate	S CN CF3

Table 3

Entry	Name	Structure
96	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2- methyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S CN H ₂ N N N N CF ₃
100	N ² -[5-cyano-2-(methylthio)pyrimidin- 4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S N N CF3
101	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- (tetrahydro-2H-pyran-4-ylmethyl)-N- [3- (trifluoromethyl)phenyl]glycinamide	S CN H ₂ N N O CF ₃
102	N²-(2-amino-5-cyano-6-{[2- (dimethylamino)ethyl]oxy]pyrimidin- 4-yl)-N-[3-(trifluoromethyl)phenyl]- L-alaninamide	H ₂ N H CF ₃
103	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-6- {[[1,1-dimethylethyl)oxy]carbonyl}- N-[3-(trifluoromethyl)phenyl]-L- lysinamide	NH ₂ NH t-Bu O

Table 3

Entry	Name	Structure
104	2-amino-4-(methylthio)-6- (methyl{(IS)-1-[6-(trifluoromethyl)- IH-benzimidazol-2- yl]ethyl}amino)pyrimidine-5- carbonitrile	NC NH2 CF3
105	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-[2- (tetrahydro-2H-pyran-4-yl)ethyl]-N- [3- (trifluoromethyl)phenyl]glycinamide	S NH2 CN N CF3
106	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3-{[2- (diethylamino)ethyl]amino}-5- (trifluoromethyl)phenyl]-L- alaninamide	S CN N CF3
107	2-amino-4-(methylthio)-6-({(1S)-1- [6-(trifluoromethyl)-1H- benzimidazol-2- yl]ethyl}amino)pyrimidine-5- carbonitrile	-S NH NH FF
108	2-{2-amino-5-cyano-6-[1-(3- trifluoromethyl-phenylcarbamoyl)- 1S-ethylamino]-pyrimidin-4- ylamino}-N-(3-trifluoromethyl- phenyl)-2S-propionamide	HN CF3 H ₂ N N N CF3

Entry	Name	Structure
109	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-(3- methylphenyl)glycinamide	NH ₂ NH ₂ N N N N N N N N N N N N N N N N N N N
110	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3-(1- methylcthyl)phenyl]glycinamide	NH ₂ S CN H
111	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-5- [imino(nitroamino)methyl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S CN NH2 NH2 NNO2 CF3
112	methyl 3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-5- (trifluoromethyl)benzoate	$\begin{array}{c} NH_2 \\ N \\ $
113	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- nitrophenyl)-L-alaninamide	S NH2 N N N NO2
114	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	NH2 NH2 NH2 CN NH2 CF3

Table 3

Entry	Name	Structure
115	N ² -[2-amino-5-cyano-6- (propyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH2 NH2 CF3
117	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- argininamide	S CN CF3
118	N ² -[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂
119	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂ NH ₂ NH ₂ NH ₂ CF ₃
120	N ² -[2-amino-5-cyano-6- (propyloxy)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂ NH ₂ NH ₂ CF ₃
121	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂ N N N CF ₃

Table 3		
Entry	Name	Structure
122	N ² -{2-amino-5-cyano-6-[{1- methylethyl)oxy]pyrimidin-4-yl}-N- [3-(trifluoromethyl)phenyl]-L- alaninamide	NH ₂
123	N-5-acetyl-N-2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S CN CF3
124	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- aminophenyl)-L-alaninamide	S CN NH2
125	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-N-[2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	NH ₂ NH S NH O CN NH O CF ₃
126	2-(methyloxy)ethyl ((48)-4-{[2- amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}-5- oxo-5-{[3- (trifluoromethyl)phenyl]amino}pentyl)carbamate	SH2 H O CF3
127	2-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	NH2 N H N H CF3

Table 3

Entry	Name	Structure
128	1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(cthyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}-pentyl)carbamate	NH ₂ CF ₃
130	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N- methyl-L-alanyl}amino)-N-[2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	S.CH ₃ Chiral Chiral Chy CH ₃ CH ₃ CF ₃ CH ₃ CO Chiral
131	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N- methyl-L-alanyl]amino)-N-[3-(4- methylpiperazin-1-yl)propyl]-5- (trifluoromethyl)benzamide	Chiral CH ₃ C
132	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N~2~- methyl-N-{3- [(trifluoromethyl)oxy]phenyl}-L- alaninamide	S.CH ₃ N Ch ₃

Table 3

Entry	Name	Structure
133	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- bromophenyl)-N-2~-methyl-L- alaninamide	H ₃ C·S CNCH ₃ H H ₂ N N N H ₃ H CH ₃ O Br
134	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-{2- {[2-(dimethylamino)ethyl]oxy}-5- [(trifluoromethyl)oxy]phenyl}-N~2~- methyl-L-alaninamide	S.CH ₃ N CH ₃ N F F H ₂ N N CH ₃ O F F
135	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N- methyl-L-alanyl}amino)-N-(2- morpholin-4-ylethyl)-5- (trifluoromethyl)benzamide	S.CH ₃ Chiral H ₂ N N CH ₃ O CH ₃ CH ₃ CF ₃
136	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N~2~- methyl-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	CH ₃ NH ₂ Chiral

Table 3

Entry	Name	Structure
137	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3-{[2- (dimethylamino)ethyl]oxy}-5- (trifluoromethyl)phenyl]-L- alaninamide	Chiral Chiral P F F F CH ₃ N CH ₃ N CH ₃ CH ₃ CH ₃ CH ₃ CH ₃
138	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}-3- oxo-3-{[3- (trifluoromethyl)phenyl]amino}propyl acetate	H ₃ C. S O CH ₃ Chiral
139	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N~1~-[3- (trifluoromethyl)phenyl]-L- glutamamide	H ₃ C _{-S} H ₂ N O Chiral H ₂ N CF ₃
140	2-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	H ₂ N ₂ N ₃ N ₄ N ₅ N ₅ N ₇ N ₇
141	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-N-hydroxy-5- (trifluoromethyl)benzamide	SCH ₃ N Chiral Chiral Chiral Chiral Chiral Chiral

Table 3

Entry	Name	Structure
142	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₃ C·S CH ₃ N-CH ₃ H ₂ N H F F
143	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-5- morpholin-4-yl-N-[3- (trifluoromethyl)phenyl]-L- norvalinamide	H ₃ C ₂ S N H F F F
144	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N~5~-[2- (methyloxy)ethyl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S.CH NH H ₂ N N CF ₃
145	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-5- (trifluoromethyl)benzoic acid	Chral CH ₃ N CH ₃ H ₂ N CF ₃ HOOO
146	methyl N~2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	H ₃ C·SH ₃ C·OO Chiral

Table 3

Entry	Name	Structure
147	N ⁵ -(aminocarbonyl)-N~2~-[2-amino- 5-cyano-6-(methylthio)pyrimidin-4- yl]-N-[3-(trifluoromethyl)phenyl]-L- ornithinamide	O NH ₂ Christ
148	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y[]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	CH ₃ Chiral
149	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutamine	H ₃ C·s HO O CHiral
150	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- serinamide	CH ₃ Chiral
151	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L- serinamide	Chiral Chiral Chiral H ₂ N N N CF ₃

	Table	
Entry	Name	Structure
152	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- argininamide	CH ₃ H ₂ N NH Crirol NH H ₂ N NH CF ₃
153	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N~2~- methyl-N ⁶ - {[(phenylmethyl)oxy]earbonyl}-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	H ₃ C. S. H ₂ N N H F F F CH ₃ O Chiral
154	N-α-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- tyrosinamide	H ₃ COOH Christ
155	N ⁵ -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	H ₃ C S N HN O NH ₂

Table 3

Entry	Name	Structure
156	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]- N-6~,N-6~-dimethyl-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	CH ₃ H ₃ C. N.CH ₃ Chiral
157	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3-[(4- methylpiperazin-1-yl)earbonyl]-5- (trifluoromethyl)phenyl]-L- alaninamide	CH ₃ Chiral
158	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-L- alanyl} amino)-N-(3-pyrrolidin-1- ylpropyl)-5- (trifluoromethyl)benzamide	CH ₃ Chiral N CH ₃ Chiral N CH ₃ CF ₃ HN O

Table 3

Entry	Name	Structure
159	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-L- alanyl]amino)-N-(2-morpholin-4- ylethyl)-5-(trifluoromethyl)benzamide	CH ₃ Chiral N CH ₃ H CH ₃ H CF ₃ H CF ₃ H CF ₃ Chiral
160	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-L- alanyl}amino)-N-[2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	CH ₃ Chiral N CH ₃ H CF ₃ HN O H ₃ C N·CH ₃
161	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-L- alanyl}amino)-N-[3-(4- methylpiperazin-1-yl)propyl]-5- (trifluoromethyl)benzamide	CH ₃ Chiral Chiral Chiral Chiral

Table 3

Entry	Name	Structure
162	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2~- methyl- N ⁶ - {[(phenylmethyl)oxy]carbonyl}-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	Chiral Chiral Chiral
163	1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate	H ₃ C CH ₃ Chiral H ₂ CH ₃ NH
164	(2S)-2-{[2-amino-5-cyano-6- (cthyloxy)pyrimidin-4-yl]amino}-3- oxo-3-{[3- (trifluoromethyl)phenyl]amino}propyl acctate	CH ₃ CN O CH ₃ CF ₃ CF ₃
165	phenylmethyl N~2~-[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-yl]-N- [3-(trifluoromethyl)phenyl]-L-alpha- glutaminate	Chiral Ch

Table 3

Entry	Name	Structure
166	N ² , N ⁵ -diacetyl-N~2~-[2- (acetylamino)-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	O CH ₃ Christ
167	2-(methyloxy)ethyl ((4S)-4-{[2- amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}-5- oxo-5-{[3- (trifluoromethyl)phenyl]amino}pentyl)carbamate	O O O CH ₃ Chrid
168	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-5- morpholin-4-yl-N-[3- (trifluoromethyl)phenyl]-L- norvalinamide	Chiral Chiral H ₂ N H F F
169	N-((4S)-4-{[2-amino-5-cyano-6- (cthyloxy)pyrimidin-4-yl]amino}-5- oxo-5-{[3- (trifluoromethyl)phenyl]amino}pentyl)-N,N-dimethylmethanaminium	CHrist CHa N. CHa N. CHa H ₂ N F F
170	Methyl N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	CH ₃ COOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO

Table 3

Entry	Name	Structure
171	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin.4-yl]- N-6~,N-6~-dimethyl-N-[3- (trifluoromethyl)phenyl]-L- lysinamide	H ₃ C _{-N} CH ₃ Chiral
172	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N~2~- methyl-N-{3- [(trifluoromethyl)oxy]phenyl}-L- alaninamide	Chiral Chiral Page 1
173	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutamine	CHral
174	N~2~-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-(3- bromophenyl)-N~2~-methyl-L- alaninamide	CH ₃ CHall CHall CHall CHall CHall
175	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]- N ¹ -[3- (trifluoromethyl)phenyl]-L- glutamamide	CHrall Chiral Chiral Chiral Chiral Chiral

Table 3

	Table	
Entry	Name	Structure
176	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	CH ₃ Chrall
177	2-(2-amino-5-cyano-6- ethoxypyrimidin-4-ylamino)-5- hydrazinyl-5-oxo-N-(3- (trifluoromethyl)phenyl)pentanamide	CH ₃ NH ₂ Chral
178	N²-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ C. Chral
179	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3-{[2- (dimethylamino)ethyl]oxy}-5- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N F F F S CH ₃ CH ₃ CH ₃ CH ₃
180	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3-{[2- (dimethylamino)ethyl]oxy]-5- (trifluoromethyl)phenyl]-L- alaninamide	Chiral Chiral P F F F F F F F F F F F F F F F F F F

Table 3

Entry	Name	Structure
181	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-(3- bromophenyl)- N ² -methyl-L- alaninamide	H ₃ C. CNCH ₃ H H ₂ N N N Br
182	phenylmethyl N²-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	H ₃ C·S O O H CF ₃
183	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L- serinamide	H ₃ C· _S N N CN O H ₂ N CF ₃
184	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]- N~5~,N~5~bis[2-(methyloxy)ethyl]- N-[3-(trifluoromethyl)phenyl]-L- ornithinamide	S.CH ₃ Chiral
185	1,1-dimethylethyl ((4S)-4-{[2-amino-5-cyano-6-(methyloxy)pyrimidin-4-yl]amino}-5-oxo-5-{[3-(trifluoromethyl)phenyl]amino}pentyl)carbamate	H ₂ N N N O CH ₃ CF ₃

Table 3

Entry	Name	Structure
186	N ⁵ -acetyl- N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y[]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	CH ₃ O CH ₃ Christ
187	N ⁵ ~-acetyl- N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	O CH ₃ Chiral O CH ₃ NH H ₂ N CF ₃
188	N²-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]- N²- methyl-N-{3- [(trifluoromethyl)oxy]phenyl}-L- alaninamide	CH ₃ N CH ₃ H OCF ₃ CH ₃ O
189	methyl 3-({N-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-L- alanyl}amino)-5- (trifluoromethyl)benzoate	H ₂ N N N CF ₃

Table 3

Entry	Name	Structure
190	3-({N-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-L- alanyl jamino)-N-[2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	Christ H ₂ N N H CF ₃ H ₃ C N CH ₃
191	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-3- morpholin-4-yl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₃ C·S Criral
192	N²-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-3- morpholin-4-yl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₃ C. Chiral
193	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-3- morpholin-4-yl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	Chral
194	N ⁵ -(aminocarbonyl)- N ² -[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-yl]-N- [3-(trifluoromethyl)phenyl]-L- ornithinamide	O NH ₂ Chiral

Table 3

Entry	Name	Structure
195	N~2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D- lysinamide	SMe H ₂ N H O F F
196	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D- lysinamide	OEt NH ₂ Chiral
197	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-O-methyl- N-[3-(trifluoromethyl)phenyl]-L- serinamide	CH ₃ CH ₃ CH ₃ CH ₃ CH ₃ CH ₃ CF ₃
198	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yI]-N~5~- (methylsulfonyl)-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	CH3 O=\$=C NH H ₂ N N N CF ₃ Chiral

35. (previously presented) A pharmaceutical composition comprising the compound according to claim 13 and a pharmaceutically acceptable carrier.

36-43. (cancelled).